SDG's Biotech Advisor to Speak on Strategies to Beat a Bear Market

Share Article

SDG Partner Sandra Wrobel will discuss insights from analyzing pre- and post-recession biotech funding data in her keynote presentation this month at PSA: The Pharmaceutical Strategy Conference.

Sandra J Wrobel


There is no silver bullet path to surviving a recession, but companies that performed better through and post-recession do have a set of characteristics we can learn from.

Management consulting firm Strategic Decisions Group (SDG) announced today that Sandra J. Wrobel, partner and managing director, will be a keynote speaker at PSA: The Pharmaceutical Strategy Conference. The conference is Sept. 28-30 in New York.

Ms. Wrobel, an expert in product and portfolio investment strategies in global health and the life sciences, will present “Besting a bio bubble: What private biotech did to beat the last bear market.” This session will examine the how companies navigated the 2008 investment downturn and what lessons can be learned. Her presentation is scheduled for 3:30 p.m. September 29.

“There is no silver bullet path to surviving a recession," said Ms. Wrobel, "but companies that performed better through and post-recession do have a set of characteristics we can learn from."

With more than 25 years of consulting and industry experience in life sciences, global health, the public sector, and public-private partnerships, Ms. Wrobel is frequently called on to help organization deal with complex problems. In 2002, she co-founded the highly regarded consulting firm Applied Strategies and helped build the company’s reputation in forecasting supply and demand for new health interventions, evaluating innovative financing mechanisms, assessing the value and risk to suppliers and donors of global markets, and understanding the potential impact of new product introduction. SDG acquired Applied Strategies in 2015. She holds an MBA from Stanford University and a BS in chemical and petroleum refining engineering from the Colorado School of Mines.

Attending the conference from SDG with Ms. Wrobel will be senior consultant Dr. Cristina Stoyanov and associate consultant Dr. Curtis Schauder. Dr. Stoyanov has more than 10 years of scientific experience in biomedical research and in public health and Dr. Schauder received his PhD in molecular biophysics and biochemistry from Yale University. Both will be available to answer questions with Ms. Wrobel following her presentation.

About Strategic Decisions Group (SDG)

Founded in 1981, Strategic Decisions Group is a management consulting firm renowned for its expertise in strategic decision-making, risk management, and value creation. Through a collaborative, team-based approach, SDG helps its clients find innovative, creative strategies to thrive today, while also helping them build internal competencies and more effective decision-making processes to meet competitive challenges in the future.

About PSA: The Pharmaceutical Strategy Conference

PSA: The Pharmaceutical Strategy Conference brings together senior level executives from pharma, biotech, government, academia, trade organizations and healthcare service providers to share, discuss and resolve fundamental challenges in biopharma.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Barbara Metzler

Jill Totenberg
The Totenberg Group
(212) 704-0352
Email >
Follow >
Strategic Decisions Group (SDG)
since: 10/2010
Like >
Strategic Decisions Group (SDG)

Visit website